Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
VA Connecticut Healthcare System, West Haven, CT, USA.
J Subst Abuse Treat. 2022 Jan;132:108509. doi: 10.1016/j.jsat.2021.108509. Epub 2021 May 29.
Persons with HIV (PWH) and opioid use disorder (OUD) can have poor health outcomes. We assessed whether intensity of behavioral treatment for OUD (BOUD) with and without medication for OUD (MOUD) is associated with improved HIV clinical outcomes.
We used Veterans Aging Cohort Study (VACS) data from 2008 to 2017 to identify PWH and OUD with ≥1 BOUD episode. We assessed BOUD intensity and ≥6 months of MOUD (methadone or buprenorphine) receipt during the 12 months after BOUD initiation. Linear regression models assessed the association of BOUD intensity and MOUD receipt with pre-post changes in log viral load (VL), CD4 cell count, VACS Index 2.0, antiretroviral treatment (ART) initiation, and ART adherence.
Among 2419 PWH who initiated BOUD, we identified five distinct BOUD intensity trajectories: single visit (39% of sample); low-intensity, not sustained (37%); high-intensity, not sustained (9%); low-intensity, sustained (11%); and high-intensity, sustained (5%). MOUD receipt was low (17%). Among 709 PWH not on ART at the start of BOUD, ART initiation increased with increased BOUD intensity (p < 0.01). Among 1401 PWH on ART at the start of BOUD, ART adherence improved more in higher-intensity BOUD groups (p < 0.01). VL, CD4 count and VACS Index 2.0 did not differ by BOUD or ≥6 months of MOUD treatment.
Among PWH and OUD who initiated BOUD, higher intensity BOUD was associated with improved ART initiation and adherence, but neither BOUD alone nor BOUD plus ≥6 months MOUD was associated with improvements in VL, CD4 count or VACS Index 2.0.
艾滋病毒感染者(PWH)和阿片类药物使用障碍(OUD)患者的健康状况可能较差。我们评估了 OUD 的行为治疗强度(BOUD)以及是否联合 OUD 治疗药物(MOUD)是否与改善 HIV 临床结局相关。
我们使用 2008 年至 2017 年退伍军人老龄化队列研究(VACS)的数据,确定了至少有 1 次 BOUD 发作的 PWH 和 OUD 患者。我们评估了 BOUD 强度以及 BOUD 发作后 12 个月内至少接受 6 个月的 MOUD(美沙酮或丁丙诺啡)。线性回归模型评估了 BOUD 强度和 MOUD 接受程度与 log 病毒载量(VL)、CD4 细胞计数、VACS 指数 2.0、抗逆转录病毒治疗(ART)开始和 ART 依从性的前后变化之间的关联。
在 2419 名开始 BOUD 的 PWH 中,我们确定了五种不同的 BOUD 强度轨迹:单次就诊(样本的 39%);低强度,不持续(37%);高强度,不持续(9%);低强度,持续(11%);高强度,持续(5%)。MOUD 接受程度较低(17%)。在开始 BOUD 时未接受 ART 的 709 名 PWH 中,随着 BOUD 强度的增加,开始接受 ART 的比例增加(p<0.01)。在开始 BOUD 时已接受 ART 的 1401 名 PWH 中,高强度 BOUD 组的 ART 依从性改善更明显(p<0.01)。VL、CD4 计数和 VACS 指数 2.0 与 BOUD 或至少 6 个月的 MOUD 治疗无关。
在开始 BOUD 的 PWH 和 OUD 中,更高强度的 BOUD 与改善 ART 起始和依从性相关,但 BOUD 本身或 BOUD 联合至少 6 个月 MOUD 治疗均与 VL、CD4 计数或 VACS 指数 2.0 的改善无关。